Free tool
FDA Approval Tracker
Last checked: Nov 20, 2026Latest source record: Aug 27, 2026Drugs@FDA last updated: Nov 18, 2026Methods & limitations
Matching approvals
8
2023 to 2026
Breakthrough
0
Accelerated
0
Priority review
3
Orphan
2
By year
NDAs and BLAs matching the filters.
- NDA
- BLA
View as table
| Year | NDA | BLA |
|---|---|---|
| 2023 | 1 | 0 |
| 2024 | 2 | 1 |
| 2025 | 1 | 0 |
| 2026 | 3 | 0 |
8 approvals
Newest first. Hover a badge for what it means.
- Lisraya (Brepocitinib Tosylate) · Priovant TherapAug 27, 2026
To treat dermatomyositis in adults
- Differin Epiduo Acne Gel (Adapalene and Benzoyl Peroxide) (Adapalene, Benzoyl Peroxide, Adapalene, Benzoyl Peroxide) · Galderma Labs LpMay 22, 2026Original approval · NDA 220736Approval letter
- Adquey (Difamilast) · Acrotech BiopharmaFeb 12, 2026
To treat mild to moderate atopic dermatitis
- Anzupgo (Delgocitinib) · Leo Pharma AsJul 23, 2025
To treat moderate-to-severe chronic hand eczema when topical corticosteroids are not advisable or produce an inadequate response
- Ebglyss (Lebrikizumab-Lbkz) · Eli Lilly and COSep 13, 2024
To treat moderate-to-severe atopic dermatitis
- Sofdra (Sofpironium Bromide) · Botanix SbJun 18, 2024
To treat primary axillary hyperhidrosis
- Zevtera (Ceftobiprole Medocaril Sodium) · IstxApr 3, 2024
To treat certain bloodstream infections, bacterial skin and associated tissue infections, and community-acquired bacterial pneumonia
- Filsuvez (Birch Triterpenes) · ChiesiDec 18, 2023
To treat wounds associated with dystrophic and junctional epidermolysis bullosa
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.